Valion Bio (VBIO) Profit After Tax (2021 - 2026)
Valion Bio (VBIO) posted quarterly Profit After Tax of $73000.0 for Q4 2025, up 105.02% year-over-year from $35606.8 in Q4 2024, and up 102.81% quarter-over-quarter from -$2.6 million in Q3 2025.
Valion Bio (VBIO) Profit After Tax (2021 - 2026) Analysis & Trends
Valion Bio's Profit After Tax history runs 5 years deep, the most recent figure standing at $73000.0 for Q4 2025.
- In Q4 2025, Profit After Tax rose 105.02% year-over-year to $73000.0; the TTM figure through Dec 2025 stood at -$6.0 million (down 5.73% YoY), while the FY2025 annual figure was -$301000.0, up 94.68% from the prior year.
- Profit After Tax for Q4 2025 stood at $73000.0, up from -$2.6 million in the prior quarter.
- The five-year high for Profit After Tax was $73000.0 in Q4 2025, with the low at -$3.7 million in Q4 2021.
- The 5-year median for Profit After Tax is -$2.0 million (2023), against an average of -$1.9 million.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 175.87% in 2022, then surged 105.02% in 2025.
- Valion Bio's Profit After Tax stood at -$3.7 million in 2021, then soared by 39.47% to -$2.3 million in 2022, then rose by 0.49% to -$2.2 million in 2023, then surged by 35.13% to -$1.5 million in 2024, then surged by 105.02% to $73000.0 in 2025.
- Business Quant data shows VBIO's Profit After Tax at $73000.0 in Q4 2025, -$2.6 million in Q3 2025, and -$1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.62 Mn |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | -2.60 Mn |
| Jun 30, 2025 | -1.93 Mn |
| Mar 31, 2025 | -1.50 Mn |
| Dec 31, 2024 | -1.46 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Mar 31, 2024 | -1.48 Mn |
| Dec 31, 2023 | -2.24 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | -2.13 Mn |
| Mar 31, 2023 | -2.12 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Jun 30, 2022 | -3.02 Mn |
| Mar 31, 2022 | -2.24 Mn |
| Dec 31, 2021 | -3.72 Mn |
| Sep 30, 2021 | -2.32 Mn |
| Jun 30, 2021 | -1.09 Mn |